Innate Pharma share price logo

Innate Pharma

NASDAQ: IPHA

$2.22

-0.01

(-0.45%)

as on

Innate Pharma Stock Performance

as on August 31, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $2.23
    $2.29
    downward going graph

    -0.45%

    Downside

    3.15%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.17
    $2.71
    downward going graph

    47.30%

    Downside

    22.07%

    Upside

    downward going graph

Innate Pharma share price movements today

Previous Close
$2.23
Open
$2.29
Volume
386.7K
Market Cap
$248.0M
Day's Low - High
$2.23 - $2.29
52 Week Low - High
$1.17 - $2.71

Innate Pharma Historical Returns

1 Month Return
+ 26.86 %
3 Month Return
+ 21.31 %
1 Year Return
+ 2.77 %
3 Year Return
-23.77 %
5 Year Return
-39.01 %

Innate Pharma Stock Fundamentals & Key Indicators

Check Innate Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$248.0M

EPS (TTM)

-0.55

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.75%

PE Ratio (TTM)

-3.41

Industry PE ratio

-1.6496124031007753

PEG Ratio

-0.3471454545454549

EBITDA

-55.8M

Revenue (TTM)

2.8M

Profit Margin

100.00%

Return On Equity TTM

593.93%

Innate Pharma Stock Valuation

Track how Innate Pharma P/E has moved over time to understand its valuation trends.

Innate Pharma in the last 5 years

  • Overview

  • Trends

Lowest (-28.15x)

December 31, 2023

Today (-2.81x)

December 31, 2025

Industry (-1.65x)

December 31, 2025

Highest (-2.81x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -2.81x

Innate Pharma vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Innate Pharma with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Innate Pharma image
Innate Pharma
BUY$248.0M-39.01%-3.41100.00%NA
Revolution Medicines image
Revolution Medicines
BUY$44.6B614.61%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$137.2B170.45%31.9286.04%NA
Moderna image
Moderna
BUY$55.1B-63.37%-7.98-12.57%NA
Regeneron image
Regeneron
BUY$85.8B17.94%19.984.86%0.44%

Stock Returns calculator for Innate Pharma Stock including INR - Dollar returns

The Innate Pharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Innate Pharma investment value today

Current value as on today

₹1,11,391

Returns

₹11,391

(+11.39%)

Returns from Innate Pharma Stock

₹2,773 (+2.77%)

Dollar Impact

₹8,618 (+8.62%)

Analyst Recommendation on Innate Pharma Stock

Based on 3 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 3 analysts, 100% of analysts recommend a 'BUY' rating for Innate Pharma. Average target price of $7

Innate Pharma Share Price Target

Get share price movements and forecasts by analysts on Innate Pharma.

What analysts predicted

68.29%UPSIDE

Target Price

$7

Current Price

$2.22

Analyzed by

3 Analysts

Target

$7.00

Innate Pharma target price $7, a slight upside of 68.29% compared to current price of $2.22. According to 3 analysts rating.

Indian Investors' Interest in Innate Pharma Stock

Search interest for Innate Pharma Stock has increased by 210% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:210% versus previous 30 day period

Innate Pharma Quarterly Profit & Loss

All numbers in Millions USD

Jun 2021
Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Jun 2024
Dec 2024
Jun 2025
Dec 2025
Total Revenue
9
2
41
8
35
16
12
0
4
-2
Gross Profit
-1
-10
28
-5
19
-3
-16
29
-15
18
Operating Income
-26
-30
4
-28
-5
-7
-26
-25
-25
-27
EBITDA
-26
-26
6
-10
0
-10
-25
-21
-25
-30
Interest Expense
0
0
0
0
0
3
0
0
0
2
Depreciation
2
2
2
2
3
1
0
1
0
0
Income Before Tax
-28
-29
2
-68
-3
-4
-24
-24
-21
-27
Income Tax Expense
-4
-7
-4
-3
-4
-
-
-
-
-2
Net Income
-23
-29
6
-64
1
-9
-24
-24
-21
-27
Net Profit Margin
-13.79%
-361.80%
69.77%
-60.71%
55.50%
-18.88%
-135.53%
10634.78%
-322.22%
-889.87%

Innate Pharma Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
32
79
68
69
12
57
51
12
2
Gross Profit
-34
10
23
20
-22
6
5
12
2
Operating Income
-39
5
-27
1
-47
-57
-12
-51
-53
EBITDA
-35
-3
-20
13
-43
-12
-1
-46
-43
Interest Expense
0
0
0
0
0
0
0
0
0
Depreciation
4
7
16
12
4
45
5
1
5
Income Before Tax
-48
2
-20
0
-45
-57
-7
-49
-49
Income Tax Expense
0
0
0
-
-
-
-
-
-
Net Income
-48
3
-20
-63
-52
-58
-7
-49
-49
Net Profit Margin
-105.33%
12.94%
34.53%
28.76%
-184.12%
10.42%
10.83%
100.00%
100.00%

Innate Pharma Quarterly Cash Flow

All numbers in Millions USD

Jun 2021
Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Jun 2024
Dec 2024
Jun 2025
Dec 2025
Net Income
-23
-21
6
-64
1
-9
-24
-24
-23
-27
Operating Cash Flow
-31
-27
1
-20
-11
-21
3
-9
-34
-23
Investing Cash Flow
0
0
0
2
0
20
0
8
7
0
Financing Cash Flow
-1
28
0
-1
-1
0
-4
-1
11
-3
Change in Cash
-32
0
0
-18
-12
0
69
-3
-5
-25

Innate Pharma Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-48
3
-20
-63
-52
-58
-7
-49
-7
Operating Cash Flow
-48
-32
34
-51
-58
-19
-32
-6
-32
Investing Cash Flow
-29
24
-62
-13
0
1
20
9
20
Financing Cash Flow
0
61
77
-1
26
-1
-1
-6
-1
Change in Cash
-76
52
50
-66
-33
-19
-13
-4
-13

Global Institutional Holdings in Innate Pharma

Funds
Holdings
GAMMA Investing LLC
0%
Morgan Stanley - Brokerage Accounts
0.05%
Exchange Traded Concepts, LLC
0%
Lion Point Capital, LP
0.09%
Barclays PLC
0%
See all

Innate Pharma News & Key Events

  • img

    Today's Timeline - 03 April

    Fri, 10:31 AM

    -

    Innate Pharma to hold one-on-one investor meetings at Kempen Life Sciences Conference on April 15-16, 2026.

Insights on Innate Pharma

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, IPHA stock has moved up by 26.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 472.8% return, outperforming this stock by 470.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 22.0% return, outperforming this stock by 45.8%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 4.86M → -2.07M (in $), with an average decrease of 71.3% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -21.34M → -27.62M (in $), with an average decrease of 14.7% per quarter

About Innate Pharma

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
OrganisationInnate Pharma
Headquarters117, Avenue de Luminy, Marseille, France, 13009
IndustryBiotechnology
CEOMr. Jonathan E. Dickinson B.Sc., M.B.A.
E-voting on sharesClick here to vote

Key Management of Innate Pharma

Name

Title

Mr. Yannis Morel Ph.D.

Executive VP & COO

Dr. Sonia Quaratino M.D., Ph.D.

Executive VP & Chief Medical Officer

Dr. François Romagné Ph.D.

Founder

Ms. Odile Belzunce

VP, Chief of Compliance & Operations Officer and Interim Head of HR

Ms. Stephanie Cornen

Vice President of Investor Relations, Communication & Commercial Strategy

Mr. Jonathan E. Dickinson B.Sc., M.B.A.

CEO & Director

Dr. Marc Bonneville Ph.D.

Founder

Mr. Jean Jacques Fournié Ph.D.

Founder

Mr. Alessandro Moretta M.D., Ph.D.

Founder

Mr. Frederic Lombard M.B.A.

Senior VP & CFO

FAQs

What is Innate Pharma share price today?

Innate Pharma share price today is $2.22 as on at the close of the market. Innate Pharma share today touched a day high of $2.29 and a low of $2.23.

What is the 52 week high and 52 week low for Innate Pharma share?

Innate Pharma share touched a 52 week high of $2.71 on and a 52 week low of $1.17 on . Innate Pharma stock price today i.e. is closed at $2.22,which is 18.08% down from its 52 week high and 89.74% up from its 52 week low.

What is Innate Pharma's market capitalisation today?

Innate Pharma market capitalisation is $0.00T as on .

How to invest in Innate Pharma Stock (IPHA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Innate Pharma on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Innate Pharma Shares that will get you 0.6757 shares as per Innate Pharma share price of $2.22 per share as on August 31, 2026 at 8:46 am IST.

What is the minimum amount required to buy Innate Pharma Stock (IPHA) from India?

Indian investors can start investing in Innate Pharma (IPHA) shares with as little as ₹95.38 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹953.80 in Innate Pharma stock (as per the Rupee-Dollar exchange rate as on ). Based on Innate Pharma share’s latest price of $2.22 as on August 31, 2026 at 8:46 am IST, you will get 4.5045 shares of Innate Pharma. Learn more about fractional shares .

What are the returns that Innate Pharma has given to Indian investors in the last 5 years?

Innate Pharma stock has given -39.01% share price returns and 30.35% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?